Share on LinkedInShare on LinkedIn

ARTICLE · 20 APRIL 2021

IP Court Issues Preliminary Injunction Against Drug In Turkey's Named Patient Programme

Gün + Partners
Gün + Partners
Contributor
Gün + Partners

Gün + Partners

We are one of the oldest and largest law firms in Turkey and are considered internationally to be...

View firm profile
Explore more from Gün + Partners

The Istanbul Civil Court for Intellectual and Industrial Rights has granted a preliminary injunction to remove a pharmaceutical product from the foreign drug list of the Turkish Medicines and Medical Devices Agency (TMMDA).

TurkeyIntellectual Property

The Istanbul Civil Court for Intellectual and Industrial Rights has granted a preliminary injunction to remove a pharmaceutical product from the foreign drug list of the Turkish Medicines and Medical Devices Agency (TMMDA). The drug was supposed to be supplied via the named patient programme (NPP) and was removed on the grounds of patent infringement. Further, the supplier company has been prevented from directly or indirectly commercialising the product, which includes its import, storage, sale and promotion, as well as possessing it for commercial purposes.

The NPP enables a pharmaceutical product to be supplied on request of a physician, in the case that it has no marketing authorisation in Turkey or the valid marketing authorisation has not yet been launched there. If approved, it is added to the foreign drug list and is generally imported by the Turkish Pharmacists' Association's Economic Enterprise (TEB) and the Social Security Institution (SSI) on a

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from